{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:02:36Z","timestamp":1758819756292,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006413","name":"Ariad Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00432-017-2378-6","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T03:33:27Z","timestamp":1490326407000},"page":"1543-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"143","author":[{"given":"Hanna L. M.","family":"Rajala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed El","family":"Missiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anniina","family":"Ruusila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn T.","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kourosh","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Markev\u00e4rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Stentoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kreutzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"2378_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y et al (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035\u20131044. doi: 10.1038\/nbt1328","journal-title":"Nat Biotechnol"},{"key":"2378_CR3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V70.4.1165.1165","volume":"70","author":"CW Caldwell","year":"1987","unstructured":"Caldwell CW, Patterson WP (1987) Relationship between T200 antigen expression and stages of B cell differentiation in resurgent hyperplasia of bone marrow. Blood 70:1165\u20131172","journal-title":"Blood"},{"key":"2378_CR4","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.leukres.2010.01.012","volume":"34","author":"G Carulli","year":"2010","unstructured":"Carulli G, Cannizzo E, Ottaviano V et al (2010) Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leuk Res 34:1336\u20131339. doi: 10.1016\/j.leukres.2010.01.012","journal-title":"Leuk Res"},{"key":"2378_CR5","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417. doi: 10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"2378_CR6","doi-asserted-by":"publisher","first-page":"e94717","DOI":"10.1371\/journal.pone.0094717","volume":"9","author":"JM Duyvestyn","year":"2014","unstructured":"Duyvestyn JM, Taylor SJ, Dagger SA, et al (2014) Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice. PLoS ONE 9:e94717. doi: 10.1371\/journal.pone.0094717","journal-title":"PLoS ONE"},{"key":"2378_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49:615\u2013619. doi: 10.1080\/10428190801896103","journal-title":"Leuk Lymphoma"},{"key":"2378_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061. doi: 10.1038\/leu.2009.38","journal-title":"Leukemia"},{"key":"2378_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","volume":"9","author":"M Ilander","year":"2014","unstructured":"Ilander M, Hekim C, Mustjoki S (2014) Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 9:17\u201323. doi: 10.1007\/s11899-013-0190-1","journal-title":"Curr Hematol Malig Rep"},{"key":"2378_CR10","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270. doi: 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"2378_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN et al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141\u20131145. doi: 10.1182\/blood-2010-03-277152","journal-title":"Blood"},{"key":"2378_CR12","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM et al (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood 119:3403\u20133412. doi: 10.1182\/blood-2011-11-390120","journal-title":"Blood"},{"key":"2378_CR13","doi-asserted-by":"publisher","first-page":"38225","DOI":"10.18632\/oncotarget.5425","volume":"6","author":"A Kim","year":"2015","unstructured":"Kim A, Seong KM, Kang HJ et al (2015) Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Oncotarget 6:38225\u201338238. doi: 10.18632\/oncotarget.5425","journal-title":"Oncotarget"},{"key":"2378_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H Lavallade de","year":"2013","unstructured":"Lavallade H de, Khoder A, Hart M et al (2013) Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 122:227\u2013238. doi: 10.1182\/blood-2012-11-465039","journal-title":"Blood"},{"key":"2378_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2141.2010.08507.x","volume":"153","author":"AM McCaig","year":"2011","unstructured":"McCaig AM, Cosimo E, Leach MT, Michie AM (2011) Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 153:199\u2013211. doi: 10.1111\/j.1365-2141.2010.08507.x","journal-title":"Br J Haematol"},{"key":"2378_CR16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.V66.5.1053.1053","volume":"66","author":"M Nitta","year":"1985","unstructured":"Nitta M, Kato Y, Strife A et al (1985) Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 66:1053\u20131061","journal-title":"Blood"},{"issue":"352\u2013363","key":"2378_CR17","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.exphem.2015.01.008","volume":"43","author":"MP Oksvold","year":"2015","unstructured":"Oksvold MP, Duyvestyn JM, Dagger SA et al (2015) The targeting of human and mouse B lymphocytes by dasatinib. Exp Hematol 43(352\u2013363):e4. doi: 10.1016\/j.exphem.2015.01.008","journal-title":"Exp Hematol"},{"key":"2378_CR18","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1002\/cncr.24432","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, De Souza Santos FP, Kantarjian H et al (2009) Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after Imatinib failure. Cancer 115:3935\u20133943. doi: 10.1002\/cncr.24432","journal-title":"Cancer"},{"key":"2378_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4137\/BMI.S22430","volume":"10","author":"M Reinwald","year":"2016","unstructured":"Reinwald M, Boch T, Hofmann W-K, Buchheidt D (2016) Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights 10:55\u201368. doi: 10.4137\/BMI.S22430","journal-title":"Biomark Insights"},{"key":"2378_CR20","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110:4055\u20134063. doi: 10.1182\/blood-2007-07-102061","journal-title":"Blood"},{"key":"2378_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3324\/haematol.12642","volume":"93","author":"R Santachiara","year":"2008","unstructured":"Santachiara R, Maffei R, Martinelli S et al (2008) Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica 93:1252\u20131255. doi: 10.3324\/haematol.12642","journal-title":"Haematologica"},{"key":"2378_CR22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.4049\/jimmunol.140.6.1861","volume":"140","author":"VO Shah","year":"1988","unstructured":"Shah VO, Civin CI, Loken MR (1988) Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol 140:1861\u20131867","journal-title":"J Immunol"},{"key":"2378_CR23","first-page":"762","volume":"88","author":"JL Steegmann","year":"2003","unstructured":"Steegmann JL, Moreno G, Alaez C et al (2003) Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 88:762\u2013768","journal-title":"Haematologica"},{"key":"2378_CR24","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood.V92.12.4758","volume":"92","author":"N Takahashi","year":"1998","unstructured":"Takahashi N, Miura I, Saitoh K, Miura AB (1998) Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 92:4758\u20134763","journal-title":"Blood"},{"key":"2378_CR25","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in Imatinib-resistant philadelphia chromosome\u2013positive leukemias. N Engl J Med 354:2531\u20132541. doi: 10.1056\/NEJMoa055229","journal-title":"N Engl J Med"},{"key":"2378_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/0092-8674(91)90011-M","volume":"65","author":"VLJ Tybulewicz","year":"1991","unstructured":"Tybulewicz VLJ, Crawford CE, Jackson PK et al (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153\u20131163. doi: 10.1016\/0092-8674(91)90011-M","journal-title":"Cell"},{"key":"2378_CR27","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.4049\/jimmunol.165.12.6872","volume":"165","author":"PA Zipfel","year":"2000","unstructured":"Zipfel PA, Grove M, Blackburn K et al (2000) The c-Abl Tyrosine Kinase Is Regulated Downstream of the B Cell Antigen Receptor and Interacts with CD19. J Immunol 165:6872\u20136879. doi: 10.4049\/jimmunol.165.12.6872","journal-title":"J Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2378-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2378-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2378-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T20:06:36Z","timestamp":1692734796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2378-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2378-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}